MiRagen’s cobomarsen misses skin treatment target in Phase II trial for lymphoma

BOULDER — One of the most prominent drug candidates in the MiRagen Therapeutics Inc. (Nasdaq: MGEN) pipeline failed to show […]
Source: BizWest

Related Articles